Introduction
============

Parkinson's disease (PD) affects one to two individuals per 1000 ([@B77]), making it the most common neurodegenerative movement disorder ([@B47]). The diagnosis is based on four clinical cardinal signs: rigidity, bradykinesia, resting tremors, and postural instability ([@B30]). PD is often preceded by a prodromal stage, which includes non-motor symptoms like mood and sleep disorders ([@B60]). In PD, motor symptoms arise from the progressive degeneration of dopaminergic (DA) neurons in the *substantia nigra* (SN) *pars compacta*. DA neurons innervate the striatum and their degeneration is associated with a significant decrease of DA striatal content ([@B47]; [@B77]). DA neurons loss is often associated with an accumulation of Lewy bodies (LB), which are formed by the aggregation of misfolded α-synuclein, mainly in the SN, but also across several brain regions ([@B71]). PD pathogenesis is associated with genetic variations and environmental risk factors that mainly comprise aging and chronic psychological stress, as well as infection, brain trauma, and exposure to pesticides or herbicides ([@B71]; [@B64]; [@B79]; [@B54]). Levodopa (L-DOPA) is the gold-standard symptomatic treatment for PD, as no DA agonist demonstrates an equal efficacy on motors symptoms. However, adverse effects limit its chronic use. Within 5--10 years of treatment, most patients experience motor complications including L-DOPA-induced dyskinesia (LID), abnormal involuntary movements that can be more debilitating than the disease itself ([@B44]).

Inflammation, among the central nervous system (CNS) and periphery, is also a main hallmark of PD ([@B78]; [@B50]; [@B28]; [@B49]; [@B41]; [@B10]). In the CNS, microglia which are known as the resident immune cells were proposed to mediate the inflammatory response in PD. The two main environmental risk factors for PD, aging, and chronic stress, are linked to increased levels of pro-inflammatory mediators in the CNS and periphery ([@B79]; [@B54]; [@B74]). Nevertheless, the implication of microglia in the development and progression of PD is still unclear, and it remains undetermined whether their alterations are a cause or consequence of DA neurons loss ([@B39]). Microglia were recently shown to exert throughout the lifespan crucial physiological roles ([@B72]), which could become compromised and contribute to PD pathophysiology. Transcriptomic studies also shed light on the complex signature of microglia, defining several phenotypes across contexts of health and disease ([@B7]; [@B19]; [@B21]; [@B83]). In the present mini-review, we aim to summarize microglial functions in health and their potential implications in PD.

Diverse Roles of Microglia in Health
====================================

The origin of microglia has long been a subject of debate until elegantly designed *in vivo* lineage studies in mice identified erythromyeloid cells from the embryonic yolk sac as their progenitors ([@B16]; [@B65]; [@B33]; [@B18]; [@B25]). These progenitors colonize the brain during the first trimester of fetal development, in both rodents, and humans, then mature into microglia ([@B33]). Thereafter, microglial pools are maintained by self-renewal, at least under normal physiological conditions ([@B22]; [@B1]).

Mature microglia which display a ramified morphology, referred to as homeostatic microglia, constantly survey the CNS environment and contribute to its maintenance and plasticity through specific molecular pathways ([@B76]; [@B33]; [@B53]; [@B63]; [@B73]). In particular, homeostatic microglia contribute to synaptogenesis, synaptic pruning, and myelination ([@B63]; [@B32]; [@B40]; [@B58]; [@B73]; [@B42]). Microglia are also required for the adaptation of the brain and behavior to the living environment ([@B76]; [@B63]; [@B73], [@B72]). Upon injury or infection, and even chronic psychological stress, microglia undergo various morphological and functional changes often designated as microglial "activation" or reactivity to pathological or traumatic challenges ([@B53]; [@B73]). Morphological and functional changes of microglia also occur during aging where these cells become "senescent," i.e., impaired in their surveillance and response to injury ([@B69]). Considering that changes in microglial density and morphology profoundly impact on their functions (summarized in **Figure [1](#F1){ref-type="fig"}**), these findings indicate that microglia could play an important role in PD.
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Microglia in Parkinson's Disease Pathophysiology
================================================

In macaque monkeys treated with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), microglia immunopositive (+) for major histocompatibility complex (MHC) class II were found to be highly heterogeneous. They showed ramified, amoeboid or multinucleated morphologies, in the SN, nigrostriatal tract, and globus pallidus. Of note, MHC class II is considered a marker of antigen presentation ([@B81]). However, in the striatum of macaque monkeys receiving MPTP, microglia mainly displayed a ramified morphology with little evidence of active phagocytosis associated with the accumulation of fat granules in their processes ([@B27]). By contrast, amoeboid microglia were observed in both the SN and striatum of mice exposed to MPTP ([@B36]; [@B84]). Differences in MPTP administration paradigms or between species could explain this apparent discrepancy ([@B27]). In fact, PD progression in humans has been shown to be best recapitulated in non-human primates (**Table [1](#T1){ref-type="table"}** summarizes different animal models used in PD research) ([@B20]).

###### 

Summary of the main animal models used in PD research.

  Animal models                                                                                                                               Symptoms                                                                                                                                                                                                                       
  ------------------------------------------ ------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  **Rodent**                                                                                                                                                                                                                                                                                                                                                                 
  6-OHDA rat model                           ↓ Locomotion, modified behavior                                                                  ↑↑↑ SN loss, ↑↑↑ striatal DA loss, no LB, unilateral lesion                                                      AIM scale available to measure LID                                                                            Not specific to DA neurons, not progressive, DA priming needed for antiparkinsonian effects
  6-OHDA mouse model                         \-                                                                                               \-                                                                                                               Poor LID                                                                                                      \-
  MPTP mouse model                           ↓ Locomotion, bradykinesia                                                                       ↑↑↑ SN neuron loss, ↑↑↑ striatal DA neuron loss, no LB                                                           Need high L-DOPA doses to induce AIM, poor LID                                                                \-
  Rotenone rat model                         ↓ Locomotion                                                                                     ↑↑ SN neuron loss, ↑↑↑ striatal DA loss, LB                                                                      \-                                                                                                            \-
  α-synuclein transgenic mouse model         Modified behavior, ↓ or ↑ motor activity                                                         SN neuron loss (variable), striatal DA loss, LB (old animals)                                                    Poor LID                                                                                                      \-
  **Non-human primate**                                                                                                                                                                                                                                                                                                                                                      
  MPTP cynomolgus and rhesus macaque model   Modified behavior, tremor and rigidity, ↓ locomotion                                             ↑↑↑ SN neuron loss, ↑↑↑ striatal DA loss, no LB (but α-synuclein accumulation), bilateral lesion (if systemic)   LID (best model), LID reappearance after L-DOPA withdrawal, different pattern of LID: stereotypic behaviors   First L-DOPA dose induces antiparkinsonian response, best to test surgical treatments
  MPTP marmoset model                        Modified behavior, tremor and rigidity, ↓ locomotion, movement indistinguishable, hyperkinesia   ↑↑↑ SN neuron loss, ↑↑↑ striatal DA loss, no LB (but α-synuclein accumulation)                                   LID                                                                                                           Allows to test surgical treatments, not the best to test anti-dyskinetic drugs
  MPTP squirrel monkey model                 Modified behavior, tremor and rigidity, ↓ locomotion                                             ↑↑↑ SN neuron loss, ↑↑↑ striatal DA loss, possibility of LB (α-synuclein aggregates)                             LID, have LID under unlesioned conditions                                                                     Limited for study of motor complication (no abnormal PD movements observed)

The following symbols are used; ↑, increase; ↓, reduction; ↑↑↑, severe; ↑↑, moderate, summary of (

Tieu, 2011

;

Blesa and Przedborski, 2014

;

Morin et al., 2014

;

Jagmag et al., 2016

;

Morissette and Di Paolo, 2018

).

Various brain regions (e.g., pons, basal ganglia, striatum, frontal, and temporal cortices) of PD patients also showed increased binding of the radiotracer ^11^C-(R)-PK11195 compared to age-matched healthy controls by positron emission tomography ([@B57]; [@B15]). The radiotracer ^11^C-(R)-PK11195 binds to 18-kDa translocator protein (TSPO) expressed mainly by microglia, in association with inflammatory stimuli ([@B46]). In the SN of post-mortem PD samples, MHC class II+ microglia were first described in 1988 ([@B43]). Since then, other studies confirmed the presence of reactive microglia in the SN of PD patients ([@B24]). Besides MHC class II, microglia were shown to express intracellular adhesion molecule (ICAM)-1, integrin receptors CD11a, the lysosomal activity marker CD68, and the scavenger receptor TLR2 in the SN, putamen, and hippocampus of PD patients ([@B28]; [@B10]). Microglia also stained positively for pro-inflammatory cytokines such as tumor necrosis factor (TNF)α and interleukin (IL)-6 in the striatum of PD patients ([@B28]). Other investigators nevertheless failed to observe evidence of microglial reactivity in the same region of PD patients ([@B35]; [@B45]). Cytokines such as IL-1β, IL-2, IL-4, IL-6, TNFα, transforming growth factor (TGF)α, and TGFβ1 were also increased at the protein level in the striatum, and in the ventricular and lumbar cerebrospinal fluid of PD patients ([@B78]; [@B50]). Additionally, high levels of interferon (IFN)γ were measured in blood plasma from PD patients ([@B49]). Taken together, this data suggests that PD patients possess an increased brain inflammatory status. Neurotoxic reactive species that microglia can produce, such as superoxide and nitric oxide, were proposed to induce cellular stress and, in turn, contribute to neuronal loss in PD ([@B5]; [@B39]). Moreover, the cerebrospinal fluid of PD patients was shown to be toxic to DA neurons *in vitro* due to the high concentration of cytokines and auto-antibodies against quinone proteins altered by DA oxidation ([@B23]; [@B51]).

Loss of Beneficial Physiological Functions
------------------------------------------

Signaling between the microglial complement receptor 3 (CR3) and its ligand, the complement component C3, enriched at synapses, plays a key role in synaptic pruning during brain circuits refinement ([@B62]). In rats chronically receiving rotenone, a pesticide acting as a mitochondrial complex I inhibitor, CR3+ microglia were more abundant in the striatum and the SN. They also possessed an enlarged cell body with shorter, stubby processes in these two regions, contrary to the cerebral cortex, suggesting an exacerbated phagocytic activity ([@B67]). Microglia release neurotrophic and anti-inflammatory factors that promote neuronal survival ([@B39]). These cells can also modulate the formation of dendritic spines through the release of brain-derived neurotrophic factor (BDNF) in mouse primary motor cortex, a role that was required for motor learning and procedural memory ([@B59]). In PD, BDNF levels were reduced in the nigrostriatal region and/or cerebrospinal fluid of PD patients and animal models, notably exposed to MPTP or 6-hydroxydopamine (6-OHDA) ([@B51]). Furthermore, glial-derived neurotrophic factor (GDNF) was shown to protect and rescue DA neurons from degeneration in models, including rats exposed to methyl-4-phenylpyridinium (MPP^+^), the active metabolite of MPTP ([@B9]; [@B52]). Additionally, in a mouse model overexpressing human mutant α-synuclein, within neurons mostly of the spinal cord, an increase in ionized calcium binding adaptor molecule 1 (IBA1)+ microglial staining was measured in this region alongside an increased co-expression of AXL ([@B12]). With TYRO3 and MER, AXL is part of the TAM receptor family of tyrosine kinases that regulates microglial phagocytic removal of apoptotic cells, notably during adult neurogenesis. In the α-synuclein transgenic mouse, loss of both receptors modestly prolonged the lifespan ([@B12]). The authors speculated that microglia might remove distressed motor neurons in PD, through TAM receptor-mediated "phagoptosis" of living neurons causing their death ([@B6]), thus accelerating PD progression ([@B12]). In this case, a beneficial microglial function was proposed to become detrimental upon disease.

Gain of Detrimental Inflammatory Functions
------------------------------------------

Midbrain DA neurons may be particularly vulnerable to detrimental microglial functions due to the abundance of these cells in this region ([@B38]). This susceptibility is also conferred by the enrichment of DA neurons with iron, a redox active element, associated with antioxidant glutathione deficiency and monoamine oxidase activity, which all contribute to DA oxidation resulting in the production of reactive species ([@B5]; [@B71]; [@B80]). This susceptibility of the SN was further emphasized by the finding that local lipopolysaccharide (LPS; a bacterial component) injection into the SN, hippocampus or cerebral cortex of wild-type rats induced neuronal loss only in the SN ([@B34]). Further *in vitro* characterization of neuron-glial cultures identified a key role for microglia in the regional sensitivity to LPS. Indeed, supplementation of microglia into cortical neuron-glial cultures was sufficient to promote LPS-induced neurotoxicity ([@B34]). Microglia might over-produce pro-inflammatory mediators and reactive species, notably when performing phagocytosis, which could lead to neuronal damage and in turn contribute to sustaining inflammation in PD ([@B82]; [@B71]). In rat primary neuron-glial cell cultures, the exogenous application of α-synuclein aggregates induced microglial transformation into amoeboid cells, which produced reactive species resulting in DA neurons loss ([@B86]). *In vitro*, neuromelanin (NM), a dark pigment formed by melanin that is found in catecholaminergic neurons (containing DA or norepinephrine) ([@B11]), induced loss of DA neurons when added to human primary mesencephalic neuron-glia cultures ([@B85]). The phagocytic clearance of NM by microglia also induced the production of superoxide, nitric oxide, hydrogen peroxide and pro-inflammatory TNFα and IL-6, which could be prevented by genetic deletion of CR3 *in vitro* ([@B85]). Besides NM, matrix metalloproteinase 3 (MMP3) and α-synuclein, which are released by degenerating DA neurons, promote microglial production of reactive species ([@B5]).

Microglia in Aging and Chronic Stress
=====================================

Normal Aging and Microglial Alterations
---------------------------------------

Aging is associated with an increased expression level of pro-inflammatory cytokines (e.g., IL-1β, IL-6, and TNFα) as well as decreased expression level of anti-inflammatory cytokines (e.g., IL-10) and anti-oxidants (e.g., glutathione levels) in rodent brain ([@B14]; [@B68]; [@B61]). Furthermore, during aging, LPS-immune-challenged mice display an exacerbated inflammatory response ([@B17]; [@B68]; [@B55]). With relevance to PD, analyses of IBA1+ microglia in the SN and striatum of wild-type mice, from birth until 24 months of age, revealed that cellular density is decreased while clustering is increased after 18 months of age in both regions ([@B66]). Moreover, microglia underwent dystrophic morphological changes in the SN (see **Figure [1](#F1){ref-type="fig"}**), such as reduced ramifications, starting at 12 months ([@B66]). In aged rhesus monkeys, an increase in human leukocyte antigen-DR (HLA-DR), a component of MHC class II+ microglia, and similar morphological alterations were observed in the SN, together with an increased prevalence of amoeboid-shaped microglia, upon administration of the MPTP toxin ([@B31]).

Chronic Stress and Pathological Aging
-------------------------------------

Aging can induce important alterations of brain homeostasis notably through its effects on microglia. In addition, aging might become "pathological" under the influence of an environmental risk factor, such as chronic psychological stress, thus triggering disease onset and progression ([@B69]).

Chronic psychological stress can accelerate cellular aging by acting on both oxidative stress and inflammation ([@B73]; [@B74]). Upon stress, microglia become "primed" and show exaggerated response to a subsequent challenge ([@B8]; [@B13]). Other than the neuroinflammation changes, chronic restraint stress in otherwise healthy rodents was associated with a loss of neurons expressing tyrosine hydroxylase (TH), the enzyme that converts L-DOPA into DA, in the SN ([@B70]; [@B56]). This TH+ neuronal loss correlated with an increase of insoluble α-synuclein monomers leading to the formation of aggregates and decreased numbers of IBA1+ microglia in the SN ([@B56]). Furthermore, when MPTP was administered after inducing stress, using the same paradigm, the loss of TH+ neurons in the SN was found to be more important in stressed rats than in unstressed littermates, which also displayed motor learning deficits (assessed with the rotarod) ([@B37]). However, different outcomes of stress on DA neurons were reported according to the type of stressor used and the brain region examined ([@B2]). The overall evidence nevertheless suggests a close relationship between chronic stress and PD, which highlights the importance of investigating microglial changes as a contributing factor to PD pathophysiology.

Another subset of microglia, "dark microglia" identified by electron microscopy, was observed in adult mice exposed to maternal immune activation ([@B26]), chronic unpredictable stress, or aging ([@B3]). Dark microglia display several markers of oxidative stress including a condensed cytoplasm and nucleoplasm, which led to their name, accompanied by dilation of the endoplasmic reticulum and Golgi apparatus, as well as mitochondrial alteration. They are highly ramified (see **Figure [1](#F1){ref-type="fig"}**) with their processes extensively encircling excitatory synapses and making direct contacts with synaptic clefts ([@B3]) suggesting an involvement in synaptic remodeling under pathological or traumatic conditions. The involvement of dark microglia in PD still remains unknown, however.

Conclusion
==========

Overall, various studies using *in vivo* and *in vitro* approaches have improved our knowledge of microglial involvement in PD despite the differences in paradigms and species used. Aging and chronic stress, two main environmental risk factors for PD, exacerbated inflammation and altered microglial functions. These changes might trigger pathological pathways notably in vulnerable CNS regions, such as the SN. Microglia produce both pro- and anti-inflammatory mediators, but upon neurodegeneration this tight equilibrium might get disrupted and become mainly pro-inflammatory. The death of DA neurons and associated reactive species production lead to pro-inflammatory and "phagoptotic" microglial phenotypes. Considering the inflammatory component of PD, it is important to study microglial implication with its onset, progression, and symptomatic treatment using L-DOPA for a translation to human patients. A better comprehension of the roles of different microglial phenotypes in PD might one day help to find anti-parkinsonian and/or anti-dyskinetic drugs targeting microglia.
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